References
1. Amerena J, Ridley D. An Update on Anticoagulation in Atrial
Fibrillation. Heart Lung Circ. 2017;26(9):911-7.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial
fibrillation in adults: national implications for rhythm management and
stroke prevention: the AnTicoagulation and Risk Factors in Atrial
Fibrillation (ATRIA) Study. Jama. 2001;285(18):2370-5.
3. Eagle KA, Cannom DS, Garcia DA. Management of Atrial Fibrillation:
Translating Clinical Trial Data into Clinical Practice. The American
Journal of Medicine. 2011;124(1):4-14.
4. Ueberham L, Dagres N, Potpara TS, et al. Pharmacological and
Non-pharmacological Treatments for Stroke Prevention in Patients with
Atrial Fibrillation. Adv Ther. 2017;34(10):2274-94.
5. January Craig T, Wann LS, Alpert Joseph S, et al. 2014 AHA/ACC/HRS
Guideline for the Management of Patients With Atrial Fibrillation. J Am
Coll Cardiol. 2014;64(21):e1-e76.
6. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused
Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients
With Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society in Collaboration With the
Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e51.
7. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the
diagnosis and management of atrial fibrillation developed in
collaboration with the European Association for Cardio-Thoracic Surgery
(EACTS): The Task Force for the diagnosis and management of atrial
fibrillation of the European Society of Cardiology (ESC) Developed with
the special contribution of the European Heart Rhythm Association (EHRA)
of the ESC. Eur Heart J. 2021;42(5):373-498.
8. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart
Rhythm Association Practical Guide on the use of non-vitamin K
antagonist oral anticoagulants in patients with atrial fibrillation. Eur
Heart J. 2018;39(16):1330-93.
9. Fawzy AM, Lip GYH. Pharmacokinetics and pharmacodynamics of oral
anticoagulants used in atrial fibrillation. Expert Opin Drug Metab
Toxicol. 2019;15(5):381-98.
10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in
nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
11. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus
warfarin in patients with atrial fibrillation. N Engl J Med.
2011;365(11):981-92.
12. Testa S, Legnani C, Antonucci E, et al. Drug levels and bleeding
complications in atrial fibrillation patients treated with direct oral
anticoagulants. J Thromb Haemost. 2019;17(7):1064-72.
13. Testa S, Paoletti O, Legnani C, et al. Low drug levels and
thrombotic complications in high-risk atrial fibrillation patients
treated with direct oral anticoagulants. J Thromb Haemost.
2018;16(5):842-8.
14. Testa S, Tripodi A, Legnani C, et al. Plasma levels of direct oral
anticoagulants in real life patients with atrial fibrillation: Results
observed in four anticoagulation clinics. Thromb Res. 2016;137:178-83.
15. Weber J, Olyaei A, Shatzel J. The efficacy and safety of direct oral
anticoagulants in patients with chronic renal insufficiency: A review of
the literature. Eur J Haematol. 2019;102(4):312-8.
16. Hirsh Raccah B, Rottenstreich A, Zacks N, et al. Drug interaction as
a predictor of direct oral anticoagulant drug levels in atrial
fibrillation patients. J Thromb Thrombolysis. 2018;46(4):521-7.
17. Ng THO, Goh JJN, Aw JWX, et al. Comparison of rivaroxaban
concentrations between Asians and Caucasians and their correlation with
PT/INR. J Thromb Thrombolysis. 2018;46(4):541-8.
18. Lin SY, Kuo CH, Yeh SJ, et al. Real-World Rivaroxaban and Apixaban
Levels in Asian Patients With Atrial Fibrillation. Clin Pharmacol Ther.
2020;107(1):278-86.
19. Shahbaz H, Gupta M. Creatinine Clearance. StatPearls. Treasure
Island (FL): StatPearls Publishing; 2021.
20. Schulman S, Kearon C. Definition of major bleeding in clinical
investigations of antihemostatic medicinal products in non-surgical
patients. J Thromb Haemost. 2005;3(4):692-4.
21. Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and
pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet.
2014;53(1):1-16.
22. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with
drugs that share its elimination pathways: pharmacokinetic effects in
healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66.
23. Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo
P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp
Ther. 2011;338(1):372-80.
24. Cheong EJY, Teo DWX, Chua DXY, et al. Systematic Development and
Verification of a Physiologically Based Pharmacokinetic Model of
Rivaroxaban. Drug Metabolism and Disposition. 2019;47(11):1291.
25. Tan HL, Tang LWT, Chin SY, et al. Investigation of the arcane
inhibition of human organic anion transporter 3 by benzofuran
antiarrhythmic agents. Drug Metab Pharmacokinet. 2021;38:100390.
26. Yang SH, Choi JS, Choi DH. Effects of HMG-CoA reductase inhibitors
on the pharmacokinetics of losartan and its main metabolite EXP-3174 in
rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase
inhibitors. Pharmacology. 2011;88(1-2):1-9.
27. Lee CA, Jones JP, 3rd, Katayama J, et al. Identifying a selective
substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug
Metab Dispos. 2012;40(5):943-51.
28. Wang E, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors
(statins) characterized as direct inhibitors of P-glycoprotein. Pharm
Res. 2001;18(6):800-6.
29. Hochman JH, Pudvah N, Qiu J, et al. Interactions of human
P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
Pharm Res. 2004;21(9):1686-91.
30. Burckhardt G. Drug transport by Organic Anion Transporters (OATs).
Pharmacol Ther. 2012;136(1):106-30.
31. Windass AS, Lowes S, Wang Y, et al. The contribution of organic
anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J
Pharmacol Exp Ther. 2007;322(3):1221-7.
32. Takeda M, Noshiro R, Onozato ML, et al. Evidence for a role of human
organic anion transporters in the muscular side effects of HMG-CoA
reductase inhibitors. Eur J Pharmacol. 2004;483(2-3):133-8.
33. Yang Q, Sun D, Pei C, et al. LDL cholesterol levels and in-hospital
bleeding in patients on high-intensity antithrombotic therapy: findings
from the CCC-ACS project. Eur Heart J. 2021.
34. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy
and safety of rosuvastatin versus atorvastatin, simvastatin, and
pravastatin across doses (STELLAR* Trial). Am J Cardiol.
2003;92(2):152-60.
35. Grgurevich S, Krishnan R, White MM, et al. Role of in vitro
cholesterol depletion in mediating human platelet aggregation. J Thromb
Haemost. 2003;1(3):576-86.
36. Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-Analysis
of Renal Function on the Safety and Efficacy of Novel Oral
Anticoagulants for Atrial Fibrillation. The American Journal of
Cardiology. 2016;117(1):69-75.
37. Baumgarten M, Gehr T. Chronic kidney disease: detection and
evaluation. Am Fam Physician. 2011;84(10):1138-48.
38. Schachter M. Chemical, pharmacokinetic and pharmacodynamic
properties of statins: an update. Fundam Clin Pharmacol.
2005;19(1):117-25.
39. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct
inhibitor of factor Xa. Am J Health Syst Pharm. 2008;65(16):1520-9.
40. Byon W, Garonzik S, Boyd RA, et al. Apixaban: A Clinical
Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet.
2019;58(10):1265-79.
41. Keizer RJ, Jansen RS, Rosing H, et al. Incorporation of
concentration data below the limit of quantification in population
pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3(2):e00131.